Literature DB >> 20652804

The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells.

Josipa Vlainić1, Maja Jazvinsćak Jembrek, Dubravka Svob Strac, Danka Pericić.   

Abstract

Zolpidem, a widely used hypnotic drug which acts through benzodiazepine binding sites, is a positive allosteric modulator of gamma-aminobutyric acid (GABA) action with preferential affinity for GABA(A) receptors containing alpha1 subunit. The pharmacological profile of zolpidem is different from that of classical benzodiazepines. The aim of this study was to find out whether zolpidem treatment triggers adaptive changes in the recombinant alpha1 subunit-containing GABA(A) receptors other than those observed following treatment with classical benzodiazepine-diazepam. Radioligand binding studies showed that 2-day exposure of human embryonic kidney (HEK) 293 cells stably expressing recombinant alpha1beta2gamma2s GABA(A) receptors to zolpidem (10 muM) up-regulated the maximum number (B (max)) of [(3)H]flunitrazepam, [(3)H]muscimol, and [(3)H]t-butylbicycloorthobenzoate ([(3)H]TBOB) binding sites without changing their affinity (K (d)), suggesting an increase in total GABA(A) receptor number. Semi-quantitative RT-PCR analysis demonstrated increased levels of alpha1 subunit mRNA, while Western blot demonstrated up-regulated gamma2 subunit proteins, suggesting that zolpidem induced de novo synthesis of receptors proteins, at both the transcriptional and translational levels. GABA-induced potentiation of [(3)H]flunitrazepam binding to membranes obtained from zolpidem-treated cells was markedly reduced, indicating allosteric uncoupling between GABA and benzodiazepine binding sites. The number of benzodiazepine and convulsant binding sites as well as the functional coupling between GABA and benzodiazepine binding sites normalized in 24 h following discontinuation of zolpidem treatment. The results of our in vitro studies suggest that a 2-day exposure of recombinant alpha1 subunit-containing GABA(A) receptors stably transfected in HEK 293 cells to zolpidem induces adaptive changes in this selective GABA(A) receptor subtype, which are not substantially different from those obtained after prolonged exposure of cells to high concentrations of diazepam.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652804     DOI: 10.1007/s00210-010-0539-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  50 in total

Review 1.  International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.

Authors:  E A Barnard; P Skolnick; R W Olsen; H Mohler; W Sieghart; G Biggio; C Braestrup; A N Bateson; S Z Langer
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

2.  Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.

Authors:  F Impagnatiello; C Pesold; P Longone; H Caruncho; J M Fritschy; E Costa; A Guidotti
Journal:  Mol Pharmacol       Date:  1996-05       Impact factor: 4.436

3.  Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms.

Authors:  N J Ali; R W Olsen
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

4.  A point mutation in the gamma2 subunit of gamma-aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity.

Authors:  A Buhr; E Sigel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 5.  Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.

Authors:  A N Bateson
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

6.  Long-range interactions in neuronal gene expression: evidence from gene targeting in the GABA(A) receptor beta2-alpha6-alpha1-gamma2 subunit gene cluster.

Authors:  M Uusi-Oukari; J Heikkilä; S T Sinkkonen; R Mäkelä; B Hauer; G E Homanics; W Sieghart; W Wisden; E R Korpi
Journal:  Mol Cell Neurosci       Date:  2000-07       Impact factor: 4.314

Review 7.  Regulation of GABA(A) receptor subunit expression by pharmacological agents.

Authors:  Mikko Uusi-Oukari; Esa R Korpi
Journal:  Pharmacol Rev       Date:  2010-02-01       Impact factor: 25.468

8.  Gamma-aminobutyric acidA receptor function is desensitised in rat cultured cerebellar granule cells following chronic flunitrazepam treatment.

Authors:  M J Brown; M D Wood; M C Coldwell; D R Bristow
Journal:  J Neurochem       Date:  1998-09       Impact factor: 5.372

9.  Molecular mechanisms of benzodiazepine-induced down-regulation of GABAA receptor alpha 1 subunit protein in rat cerebellar granule cells.

Authors:  M J Brown; D R Bristow
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  Sedative and anticonvulsant effects of zolpidem in adult and aged mice.

Authors:  Danka Pericić; Josipa Vlainić; Dubravka Svob Strac
Journal:  J Neural Transm (Vienna)       Date:  2008-01-24       Impact factor: 3.575

View more
  3 in total

Review 1.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

2.  Differential effects of short- and long-term zolpidem treatment on recombinant α1β2γ2s subtype of GABA(A) receptors in vitro.

Authors:  Josipa Vlainić; Maja Jazvinšćak Jembrek; Toni Vlainić; Dubravka Švob Strac; Danka Peričić
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

3.  Strategies of Functional Foods Promote Sleep in Human Being.

Authors:  Yawen Zeng; Jiazhen Yang; Juan Du; Xiaoying Pu; Xiaomen Yang; Shuming Yang; Tao Yang
Journal:  Curr Signal Transduct Ther       Date:  2014-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.